5 Biotech Penny Stocks to Buy Now

3. Agile Therapeutics, Inc. (NASDAQ:AGRX)

Number of Hedge Fund Holders: 6     

Agile Therapeutics, Inc. (NASDAQ:AGRX) operates as a women’s healthcare firm. The company beat market estimates on earnings per share for the third quarter by $0.01 and reported a revenue of $1.2 million over the period. 

H.C. Wainwright analyst Oren Livnat has a Buy rating on Agile Therapeutics, Inc. (NASDAQ:AGRX) stock with a price target of $2.5. In a recent investor note, the analyst noted that the company was driving steady growth through the flagship Twirla product. 

Among the hedge funds being tracked by Insider Monkey, New York-based investment firm Perceptive Advisors is a leading shareholder in Agile Therapeutics, Inc. (NASDAQ:AGRX) with 15.9 million shares worth more than $15 million.